Payment overview · 2025
General Payments
$49.27
3 reported records · 3 companies
Healthcare provider profile · identity verified
Timothy J Burrell, MD
Allopathic & Osteopathic Physicians|Family Medicine · SPARTANBURG, SC · NPI 1457672289
Verified facts
What the public records show
CMS Open Payments records show Timothy J Burrell, MD received $49.27 in general payments during 2025 across 3 reported records.
Inspire Medical Systems, Inc. accounted for 36.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.83 | 36.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.08 | 32.6% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.36 | 31.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $49.27 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 982 | 327 |
| Amlodipine Besylate | Amlodipine Besylate | 665 | 220 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 623 | 210 |
| Levothyroxine Sodium | Levothyroxine Sodium | 479 | 138 |
| Pioglitazone Hcl | Pioglitazone Hcl | 463 | 164 |
| Lisinopril | Lisinopril | 409 | 141 |
| Simvastatin | Simvastatin | 368 | 121 |
| Metformin Hcl | Metformin Hcl | 346 | 115 |
| Omeprazole | Omeprazole | 328 | 110 |
| Pantoprazole Sodium | Pantoprazole Sodium | 314 | 106 |
| Gabapentin | Gabapentin | 309 | 117 |
| Jardiance | Empagliflozin | 290 | 92 |
| Losartan Potassium | Losartan Potassium | 261 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 242 | 83 |
| Meloxicam | Meloxicam | 231 | 93 |
| Metformin Hcl Er | Metformin Hcl | 212 | 74 |
| Lorazepam | Lorazepam | 192 | 47 |
| Furosemide | Furosemide | 186 | 75 |
| Ezetimibe | Ezetimibe | 185 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 64 |
| Carvedilol | Carvedilol | 170 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 65 |
| Famotidine | Famotidine | 151 | 52 |
| Montelukast Sodium | Montelukast Sodium | 138 | 42 |
| Ozempic | Semaglutide | 137 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 136 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 50 |
| Mounjaro | Tirzepatide | 129 | 40 |
| Enalapril Maleate | Enalapril Maleate | 125 | 40 |
| Tramadol Hcl | Tramadol Hcl | 124 | 34 |
| Potassium Chloride | Potassium Chloride | 123 | 49 |
| Allopurinol | Allopurinol | 120 | 49 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 120 | 47 |
| Mirtazapine | Mirtazapine | 118 | 30 |
| Trazodone Hcl | Trazodone Hcl | 108 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 103 | 39 |
| Fenofibrate | Fenofibrate | 102 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 38 |
| Alendronate Sodium | Alendronate Sodium | 96 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 34 |
| Tradjenta | Linagliptin | 88 | 31 |
| Clonazepam | Clonazepam | 87 | 17 |
| Glipizide Er | Glipizide | 86 | 28 |
| Eliquis | Apixaban | 85 | 30 |
| Sertraline Hcl | Sertraline Hcl | 85 | 30 |
| Valsartan | Valsartan | 85 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 77 | 31 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 76 | 67 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | 21 |
| Buspirone Hcl | Buspirone Hcl | 74 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 24 |
| Bupropion Xl | Bupropion Hcl | 65 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 19 |
| Irbesartan | Irbesartan | 61 | 19 |
| Pregabalin | Pregabalin | 59 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 18 |
| Telmisartan | Telmisartan | 51 | 20 |
| Repatha Sureclick | Evolocumab | 50 | suppressed |
| Celecoxib | Celecoxib | 49 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 19 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 47 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 20 |
| Lovastatin | Lovastatin | 45 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 17 |
| Benazepril Hcl | Benazepril Hcl | 43 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 42 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 15 |
| Estradiol | Estradiol | 41 | 16 |
| Glimepiride | Glimepiride | 41 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 13 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 39 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 12 |
| Spironolactone | Spironolactone | 38 | 17 |
| Warfarin Sodium | Warfarin Sodium | 38 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 37 | 15 |
| Alprazolam | Alprazolam | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | 12 |
| Dutasteride | Dutasteride | 35 | 13 |
| Finasteride | Finasteride | 35 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 35 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 35 | 12 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 35 | 12 |
| Novolog Flexpen | Insulin Aspart | 34 | 11 |
| Diazepam | Diazepam | 33 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Olanzapine | Olanzapine | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | 13 |
| Linzess | Linaclotide | 30 | 13 |
| Temazepam | Temazepam | 30 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | 12 |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 13 |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 20 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Prednisone | Prednisone | 19 | 19 |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Desloratadine | Desloratadine | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 12 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Desoximetasone | Desoximetasone | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | 11 |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $49.27 · 3 records | Inspire Medical Systems, Inc. | CONTRAVE, INSPIRE, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error